Antisense therapeutics (original) (raw)
- Industry Trends
- Published: 01 April 1999
Nature Biotechnology volume 17, pages 403–404 (1999)Cite this article
- 149 Accesses
- 29 Citations
- Metrics details
Antisense molecules are stretches of single-stranded nucleic acid that target and bind with a specific messenger RNA, interfering with and even preventing the translation or overexpression of the protein encoded by the mRNA. They are referred to as antisense because the "sense" sequence and orientation of an mRNA is the one that directly translates itself into protein, whereas "antisense" is the complementary strand that hybridizes with the mRNA and prevents it from carrying out its function. The ability to interfere with a critical point along the gene expression and protein synthesis pathway is what makes antisense such an attractive molecular therapeutic platform. In principle, antisense molecules can be applied to any disease in which protein overexpression or even gene activation is detrimental, and are now being used to dissect gene function as well as to develop therapeutics against a wide variety of diseases.
Historical perspective
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
References
- Orkin, S.H. J. Biol. Chem. 252, 5606–5608 (1977).
CAS PubMed Google Scholar - Wortzman, M.S. & Baker, R.F. Biochim. Biophys. Acta 609, 84–96 (1980).
Article CAS Google Scholar - Rosenberg, U.B. et al. Nature 313, 703–706 (1985).
Article CAS Google Scholar - Harland, R. & Weintraub, H. J. Cell. Biol. 101 , 1094–0199 (1985).
Article CAS Google Scholar - Li, Y.X. et al. Virology 255, 138–149 ( 1999).
Article CAS Google Scholar - Naka, K. et al. Biochem. Biophys. Res. Commun. 255, 753– 758 (1999).
Article CAS Google Scholar - Monteith, D.K. et al. Toxicol. Sci. 46, 365–374 (1998).
CAS PubMed Google Scholar - Nielsen, P.E. Curr. Opin. Biotechnol. 10, 71–75 (1999).
Article CAS Google Scholar - Flechsler, I. et al. Adv. Exp. Med. Biol. 451, 469– 472 (1998).
Article CAS Google Scholar - Im, S.A. et al. Cancer Res. 59, 895–900 (1999).
CAS PubMed Google Scholar - Desai, R.P. & Papoutsakis, E.T. Appl. Environ. Microbiol. 65, 936–945 ( 1999).
CAS PubMed PubMed Central Google Scholar - Crooke, S.T. & Bennett, F.C. Ann. Rev. Pharmacol. Toxicol. 36, 107–129 ( 1996).
Article CAS Google Scholar - Good, L. & Nielsen, P.E. Nat. Biotechnol. 16 , 355–358 (1998).
Article CAS Google Scholar - Ecker, D.J. & Freier, S.M. Nat. Biotechnol. 16 , 332 (1998).
Article CAS Google Scholar
Author information
Authors and Affiliations
- vice president for business development at Argonex Inc., 2044 India Road, Charlottesville, 22901, VA
Aris Persidis
Authors
- Aris Persidis
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Persidis, A. Antisense therapeutics.Nat Biotechnol 17, 403–404 (1999). https://doi.org/10.1038/7973
- Issue Date: 01 April 1999
- DOI: https://doi.org/10.1038/7973
This article is cited by
Silencing human genetic diseases with oligonucleotide-based therapies
- Tamara Martínez
- Natalia Wright
- Covadonga Pañeda
Human Genetics (2013)
Antisense cancer therapy: The state of the science
- David M. Kushner
- Robert H. Silverman
Current Oncology Reports (2000)